Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer

<table class="fixed-width table-group" id="tab6"><tr><td><table class="table"><colgroup><col style="width:14.65em"/><col style="width:3.80em"/><col style="width:3.92em"/></colgroup><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Correlations UP2   <br/>in group of BC</td><td class="align_center">R</td><td class="align_center">p</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">UP2 (urine) vs age</td><td class="align_center">0.296</td><td class="align_center">0.021</td></tr><tr><td class="align_left">UP2 (plasma) vs sex</td><td class="align_center">0.420</td><td class="align_center">≤0.001</td></tr><tr><td class="align_left">UP2 (urine) vs UP3a (urine)</td><td class="align_center">0.491</td><td class="align_center">≤0.001</td></tr><tr><td class="align_left">UP2 (urine) vs 8-OHdG (urine)</td><td class="align_center">0.331</td><td class="align_center">0.009</td></tr><tr><td class="align_left">UP2 (urine) vs GST<i>π</i> (urine)</td><td class="align_center">0.364</td><td class="align_center">0.019</td></tr><tr><td class="align_left">UP3a (plasma) vs TAC (urine)</td><td class="align_center">-0.476</td><td class="align_center">≤0.001</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>R: Spearman correlation coefficient; p: level of significance.<br/></div></td></tr></table>

<div>Correlations between UP2 and age, sex, and other markers in BC group.</div>

BioMed Research International

tab6

Table 6

Table 6: Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer 

Table 6 | Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer 